Enhancement of anti-tumor immunity in RAS-addicted cancers with tri-complex RAS(ON) inhibitors
Speaker: Elsa Quintana, Pharm.D., Ph.D. Senior Director Cancer Immunology, Revolution Medicines, Redwood City, USA RAS mutations (RASMUT), the most frequent oncogenic alterations in human cancers, promote carcinogenesis through sustained cellular proliferation...
